Our findings demonstrate that while semaglutide drives robust weight loss during active treatment, only the combination of PT150 and semaglutide confers protection against post-treatment weight regain
Past research has shown a general alignment between GLP-1 usage and declining obesity rates across age groups, with the exception of those aged 65 and older, for whom the reported effectiveness of GLP-1 drugs is lower
Active eating disorder If you are managing binge eating disorder or another eating disorder that tirzepatide has helped control, stopping the medication requires coordination with a mental health professional who specializes in eating disorders
Not a sole therapy an adjunct, not a replacement for treating the underlying cause
Bomba M, Granzotto A, Castelli V, Massetti N, Silvestri E, Canzoniero LMT, et al